Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
BOTHELL, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam...
Clinical Trial
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
- Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million - Q3 2022 North American Revenue Growth of 19%...
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations,...
Helius Salutes Physical Therapists for Their Role in Helping People with MS Improve Their Gait
Company Spotlights its Appreciation to Physical Therapists Trained in its Innovative PoNS Therapy™ in Honor of National Physical Therapy MonthNEWTOWN,...
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022...
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform,...
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trialsBOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE)...
VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)
• Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months • 80% of...
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine...
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement...
Immuron strategic investment in leading gut health biotech Ateria Health
Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately...
Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022
First presentation of ERADICATE phase 3 study dataStudy met its primary and secondary endpoints comparing ceftobiprole versus daptomycin with or...
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022...
Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia
PHILADELPHIA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative...
DICE Announces Pricing of Upsized Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its...
BioSyent Initiates First Dividend
MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce...
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
• No safety concerns noted in ongoing clinical trial• Study timeline remains on track MALVERN, Pa., Oct. 12, 2022 (GLOBE...
Axiom Exhibiting at Outsourcing in Clinical Trials New England 2022
TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services...
Sientra Announces Preliminary Unaudited Third Quarter Financial Results and Signing of Senior Secured Loan Facilities With Deerfield Management
Anticipates total third quarter net sales of $21.5-$22.5 million, up 10-15% compared to the prior year period Restructured balance sheet...